Core Viewpoint - Quest Diagnostics Inc. is successfully investing in Advanced Diagnostics to enhance patient care and drive growth through strategic acquisitions and operational excellence [1][3]. Group 1: Financial Performance - Over the past year, Quest Diagnostics' stock has increased by 25.2%, outperforming the industry growth of 2.9% and the S&P 500's rise of 10.6% [2]. - The company has a market capitalization of $18.38 billion and an earnings yield of 5.85%, which is higher than the industry's yield of 4.32% [2]. - Quest Diagnostics has consistently surpassed earnings estimates in the last four quarters, achieving an average surprise of 3.75% [2]. Group 2: Growth Drivers - The Advanced Diagnostics segment includes specialized tests such as molecular genomics and oncology tests, contributing to double-digit revenue growth across various clinical areas in 2024 [3]. - Women's health growth is primarily driven by prenatal and hereditary genetic testing, with a notable increase in self-collection options for genital tract infection testing [4]. - The company is transitioning 75 health systems to a commercial phase for the Haystack MRD blood test, with expected revenues in 2025 [4]. Group 3: Strategic Acquisitions - Recent outreach acquisitions have allowed Quest Diagnostics to expand into key geographic areas and improve access and affordability for health systems [5]. - The acquisition of LifeLabs has strengthened its presence in the Canadian market, while other acquisitions have enhanced its AI and digital pathology capabilities [6]. Group 4: Operational Excellence - Quest Diagnostics is implementing automation and AI to enhance quality, service, and efficiency, achieving 3% annual cost savings through its Invigorate program [7]. - The Clifton, New Jersey lab is a hub for automation and AI solutions, including enhanced tuberculosis testing and improved requisition processing [9]. Group 5: Challenges - The company's long-term debt stands at $5.62 billion, with cash and cash equivalents at only $549 million, raising concerns about solvency [10]. - Quest Diagnostics faces intense competition from LabCorp and other commercial laboratories, with a focus on service quality and turnaround times [11]. Group 6: Earnings Estimates - The Zacks Consensus Estimate for Quest Diagnostics' 2025 earnings per share has decreased by 1 cent to $9.69, with projected revenues of $10.77 billion, indicating a 9.1% growth from the previous year [12].

Company Overview - Quest Diagnostics Inc. has announced a collaboration with Google Cloud to enhance data management, analytics, and patient experience [1] - The company currently has a market capitalization of $18.65 billion [3] - In 2024, Quest Diagnostics has managed over 80 billion data points and fulfilled more than 200 million test requisitions [6] Collaboration with Google Cloud - The partnership aims to strengthen Quest Diagnostics' hybrid cloud strategy by enhancing data and AI capabilities [1] - Quest will utilize Google Cloud's data analytics and generative AI technologies, including Google Agentspace, to automate tasks and improve operations [4] - The collaboration will focus on improving patient engagement and providing personalized health insights [5] Financial Performance and Projections - According to the Zacks Consensus Estimate, Quest Diagnostics' earnings are expected to grow by 8.6% in 2025, with a 9.1% increase in revenues [3] - The company has delivered an average earnings beat of 3.7% over the trailing four quarters [3] Market Trends - The global AI data management market was valued at $25.5 billion in 2023 and is projected to grow at a compound annual growth rate of 22.7% through 2030 [7] - Key drivers for this growth include advancements in AI and Machine Learning, Big Data, and increasing demand for data-driven decision-making [7] Recent Developments - Quest Diagnostics announced the acquisition of select assets from Fresenius Medical Care's Spectra Laboratories to provide laboratory services related to end-stage kidney disease [9] - In the past year, shares of Quest Diagnostics have increased by 29.2%, outperforming the industry growth of 5.1% [10]

Core Insights - Quest Diagnostics has announced a collaboration with Google Cloud to enhance data management, analytics, and patient experiences through advanced technologies [1][2][3] Company Strategy - The collaboration will utilize Google Cloud's generative AI and data analytics technologies, including Google Agentspace, to automate tasks and improve operations across various areas such as R&D and customer experience [2][4] - Quest aims to streamline its systems to enhance data quality, management, and security, while also exploring the use of generative AI to improve patient engagement and empower physicians with insights [3][4] Industry Impact - This partnership is significant as it marks one of the first instances of a national laboratory provider leveraging generative AI across multiple operational areas, indicating a shift towards more personalized and proactive healthcare solutions [2][4] - The collaboration is expected to strengthen Quest's hybrid cloud strategy, enhancing its data and AI capabilities while ensuring compliance with HIPAA regulations for data privacy and security [4][5] Performance Metrics - In 2024, Quest Diagnostics processed over 200 million test requisitions and managed more than 80 billion datapoints, showcasing its extensive operational scale [4]

Quest Diagnostics (DGX) has achieved impressive growth over the past year, with its shares rising 38%. It has outperformed the industry’s 7.7% rise and the S&P 500 composite’s 17.1% gain.Presently carrying a Zacks Rank #3 (Hold), the renowned clinical laboratory continues to demonstrate robust momentum in its core customer channel, supported by a growing utilization of the Advanced Diagnostics portfolio. Strategic outreach acquisitions and a strong focus on driving operational improvements further bode well ...

Quest Diagnostics Inc. (DGX) benefits from its robust utilization of the Advanced Diagnostics portfolio offerings. The company also expands through strategic acquisitions, completing eight transactions in 2024. A strong focus on operational excellence is highly encouraging for the stock. Meanwhile, the adverse impacts of the broader industry challenges and fierce competitive landscape pose risks to its operations.In the past year, this Zacks Rank #3 (Hold) stock has rallied 38% compared with the industry’s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 001-12215 Quest Diagnostics Incorporated 500 Plaza Drive Secaucus, NJ 07094 (973) 520-2700 Delaware 16-1387862 ...

SECAUCUS, N.J., Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 19, 2025 at the New York Stock Exchange. During the event, Jim Davis, Chairman, CEO and President, Sam Samad, Executive Vice President and CFO, and other senior executives will provide updated views of the U.S. laboratory market, and the company's business strategy, ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

Quest Diagnostics (DGX) is gaining from advanced diagnostics offerings and strategic acquisitions. Rising debts and industry challenges continue to dent growth. The stock carries a Zacks Rank #3 (Hold).Factors Driving DGX StockQuest Diagnostics’ growth in the Physician Lab Services is backed by new customer wins, growing utilization of the company’s Advanced Diagnostics portfolio and contributions from acquisitions. The ongoing strength in healthcare utilization boosted growth throughout 2024. Quest Diagnos ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What a ...